This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
THE ENDOCANNABINOID SYSTEM AND MOOD. Our moods are affected by our environment, life situations, genetics, and brain activity. Some individuals are simply happier than others, and research on CB1 (cannabinoid) receptor genes gives us some clues to why that happens. [1] However, even though some are seemingy genetically destined to find and maintain happiness easier, other variables in life cannot be minimized.
This week medical cannabis patient advocacy groups from Argentina, Mexico, Uruguay, France, Germany, New Zealand, the Netherlands, South Africa, and the United States travelled to Geneva, Switzerland to present to world leaders their recommendations for rescheduling cannabis at the 40th meeting of the World Health Organization's (WHO) Expert Committee on Drug Dependence (ECDD).
As Cannabis sales soar around the world, Cannabidiol oil (CBD) is garnering more excitement than the market can stand. Recent clinical studies support its efficacy in burning fat cells, delaying the onset of chronic disease indicators, treating mental health conditions, and killing bacteria. Pharma companies have repositioned CBD oil from a product derivative of the Cannabis plant to a strong market competitor.
Businesses rely strongly on converting new customers which can be a unique experience for a cannabis dispensary. Even with the majority of U.S. citizens voicing their support for marijuana legalization, the plant is still approached with a sense of taboo from many that grew up through decades of uninformed Reefer Madness -style propaganda and Reagan-era PSAs that seemed to justify a schedule I classification that relegated marijuana to the same notoriety as heroin.
Speaker: Jonathan Bench, International Cannabis and Securities Business Attorney at Harris Bricken
The U.S. cannabis industry is still in its infancy, even though states began engaging with legalization in one form or another in the late 1990s. Today, many opportunities exist for individuals and businesses that want to engage in the industry. Some want to directly own licensed businesses, while others prefer to keep the industry at an arm’s length and merely profit from it.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content